PRAX Stock Overview
A clinical-stage biopharmaceutical company, engages in the development of therapies for central nervous system disorders characterized by neuronal excitation-inhibition imbalance.
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
Praxis Precision Medicines, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$47.46 |
| 52 Week High | US$67.21 |
| 52 Week Low | US$12.60 |
| Beta | 2.88 |
| 1 Month Change | -12.98% |
| 3 Month Change | -13.25% |
| 1 Year Change | 213.27% |
| 3 Year Change | -83.58% |
| 5 Year Change | n/a |
| Change since IPO | -88.62% |
Recent News & Updates
Recent updates
Companies Like Praxis Precision Medicines (NASDAQ:PRAX) Are In A Position To Invest In Growth
May 14
Praxis: 2nd Half 2024 ET Readout Could Lead To U.S. Regulatory Filing
Mar 26Is There An Opportunity With Praxis Precision Medicines, Inc.'s (NASDAQ:PRAX) 26% Undervaluation?
Feb 27Here's Why Praxis Precision Medicines (NASDAQ:PRAX) Must Use Its Cash Wisely
Nov 29Can Praxis Precision Medicines (NASDAQ:PRAX) Afford To Invest In Growth?
Aug 14Can Praxis Precision Medicines (NASDAQ:PRAX) Afford To Invest In Growth?
Feb 10Here's Why Praxis Precision Medicines (NASDAQ:PRAX) Must Use Its Cash Wisely
Oct 21Praxis Precision Medicines GAAP EPS of -$1.32 misses by $0.02
Aug 08Praxis: MDD Trial Failure May Not Mean An End To Entire Pipeline
Jun 10We're Keeping An Eye On Praxis Precision Medicines' (NASDAQ:PRAX) Cash Burn Rate
May 15Companies Like Praxis Precision Medicines (NASDAQ:PRAX) Are In A Position To Invest In Growth
Jan 27Praxis Precision Medicines: Genetic Medicines For Neurological Disease
Nov 23We're Not Very Worried About Praxis Precision Medicines' (NASDAQ:PRAX) Cash Burn Rate
Oct 14Praxis' PRAX-562 wins Orphan Drug designation for rare encephalopathy
Apr 30Companies Like Praxis Precision Medicines (NASDAQ:PRAX) Are In A Position To Invest In Growth
Mar 12Read This Before Selling Praxis Precision Medicines, Inc. (NASDAQ:PRAX) Shares
Jan 18Praxis Precision's pediatric epilepsy therapies nab Rare Pediatric and Orphan Drug tags in U.S.
Jan 07Praxis Precision Medicine plummets 27% on clinical hold on lead drug
Nov 10Shareholder Returns
| PRAX | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 7.7% | -0.4% | -0.6% |
| 1Y | 213.3% | 5.5% | 22.2% |
Return vs Industry: PRAX exceeded the US Biotechs industry which returned 5.4% over the past year.
Return vs Market: PRAX exceeded the US Market which returned 22.3% over the past year.
Price Volatility
| PRAX volatility | |
|---|---|
| PRAX Average Weekly Movement | 10.9% |
| Biotechs Industry Average Movement | 10.7% |
| Market Average Movement | 5.8% |
| 10% most volatile stocks in US Market | 15.7% |
| 10% least volatile stocks in US Market | 2.9% |
Stable Share Price: PRAX's share price has been volatile over the past 3 months.
Volatility Over Time: PRAX's weekly volatility (11%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2015 | 82 | Marcio De'Souza | praxismedicines.com |
Praxis Precision Medicines, Inc., a clinical-stage biopharmaceutical company, engages in the development of therapies for central nervous system disorders characterized by neuronal excitation-inhibition imbalance. It is developing ulixacaltamide, a small molecule inhibitor of T-type calcium channels that is in Phase III clinical trial for the treatment of essential tremor; PRAX-562 for the treatment of pediatric patients with developmental and epileptic encephalopathies (DEE); and PRAX-628 to treat focal epilepsy. The company also develops PRAX-222 for the treatment of pediatric patients with early-onset SCN2A-DEE; PRAX-020 to treat KCNT1 related epilepsies; PRAX-080 for the treatment of PCDH19; and PRAX-090 and PRAX-100 for SYNGAP1 and SCN2A-LoF.
Praxis Precision Medicines, Inc. Fundamentals Summary
| PRAX fundamental statistics | |
|---|---|
| Market cap | US$811.94m |
| Earnings (TTM) | -US$125.37m |
| Revenue (TTM) | US$2.20m |
369.9x
P/S Ratio-6.5x
P/E RatioIs PRAX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| PRAX income statement (TTM) | |
|---|---|
| Revenue | US$2.20m |
| Cost of Revenue | US$88.25m |
| Gross Profit | -US$86.05m |
| Other Expenses | US$39.32m |
| Earnings | -US$125.37m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -7.33 |
| Gross Margin | -3,920.32% |
| Net Profit Margin | -5,711.85% |
| Debt/Equity Ratio | 0% |
How did PRAX perform over the long term?
See historical performance and comparison